Please use this identifier to cite or link to this item:
Induction of Prophylactic, Theraputic, and Cytotoxic Activity using Solubized Tumor Antigens
|Title:||Induction of Prophylactic, Theraputic, and Cytotoxic Activity using Solubized Tumor Antigens|
|Issue Date:||15 Jan 2014|
|Publisher:||University of Hawaii at Manoa|
|Abstract:||Immunoprophylaxis was developed in syngeneic C3H/Strong mice against ip implants of spontaneous (MTV) induced mouse mammary tumor by sensitization of the host with id injections of solubilized 3 M KCl antigens of transplantable mammary tumor. Ten days after the.2nd id injection of 3 M KCl antigens mice were challenged ip with 5 x 104 viable tumor cells. Optimal protection was found after pretreatment with 3 M KCl solubilized tumor anti-gens (1. 0 mg. protein) with BCG (2-8 x 104 Tice organisms) as evi denced by a 60% survival after 120 days. Control groups with 5 x 104 cells ip died in 38 +/- 2 days. A maximum immunizing dose of 5.0 mg. 3 M KCl antigens elicited virtually no effect upon animal survival with animals dying within 3-5 days of the control. A program solely of immunotherapy with 3 M KCl solubilized tumor antigens+ BCG (1. 0 mg. 3 M KCl antigens+ 2-8 x 104 Tice organisms id weekly) was administered to mice days 0, l, 3, and 7 after ip inoculation of 5 x 104 viable tumor cells. Treatment with 3 M KCl antigens+ BCG on day 0 and day 1 controlled tumor growth with 80-90% being free of neoplastic disease at 120 days. Therapy begun on day 7 led to 100% mortality by day 47. Treatment with BCG alone led to tumor enhancement with 100% death in 32+/- 2 days.|
|Rights:||All UHM Honors Projects are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission from the copyright owner.|
|Appears in Collections:||Honors Projects for Biology|
Please contact firstname.lastname@example.org if you need this content in an alternative format.
Items in ScholarSpace are protected by copyright, with all rights reserved, unless otherwise indicated.